ArticleKidney international reports2021
Use of the Selective Cytopheretic Device in Critically Ill Children.
Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI)
A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients With Acute Kidney Injury Requiring Continuous Kidney Replacement Therapy
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Novel extracorporeal therapies in children.Pediatric nephrology (Berlin, Germany) · 2026Article
- Continuous Kidney Replacement Therapy in Pediatric Intensive Care: A Practical Guide for Clinicians.Indian pediatrics · 2026Review
- Extracorporeal therapies in sepsis: a comprehensive review of the Selective Cytopheretic Device, Polymyxin B and Seraph cartridges.Renal failure · 2025Review
- Selective Cytopheretic Device Therapy in the Context of Extracorporeal Membrane Oxygenation.Medicina (Kaunas, Lithuania) · 2025Review
- Extracorporeal pediatric renal replacement therapy: diversifying application beyond kidney failure.Pediatric nephrology (Berlin, Germany) · 2025Review
- Selective Cytopheretic Device (QUELimmune): A Leukocyte Processing, Immunomodulatory Device.Journal of the American Society of Nephrology : JASN · 2025Article
- Article
- Immunomodulatory effects of a cell processing device to ameliorate dysregulated hyperinflammatory disease states.Scientific reports · 2024Article
- Increasing Eligibility to Transplant Through the Selective Cytopheretic Device: A Review of Case Reports Across Multiple Clinical Conditions.Transplantation direct · 2024Article
- Selective Cytopheretic Device Use in Continuous Kidney Replacement Therapy in Children: A Cohort Study With a Historical Comparator.Kidney medicine · 2024Article
- Extracorporeal Organ Support for Burn-Injured Patients.European burn journal · 2024Review
- Sequential Extracorporeal Therapy of Pathogen Removal Followed by Cell-Directed Extracorporeal Therapy in Streptococcal Toxic Shock Syndrome Refractory to Venoarterial Extracorporeal Membrane Oxygenation: A Case Report.Critical care explorations · 2024Article
- Safety Summary of the Selective Cytopheretic Device: A Review of Safety Data Across Multiple Clinical Trials in ICU Patients With Acute Kidney Injury and Multiple Organ Failure.Critical care explorations · 2023Review
- Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2023Review
- Translation of immunomodulatory therapy to treat chronic heart failure: Preclinical studies to first in human.PloS one · 2023Article
- Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review.Frontiers in immunology · 2023Review
- Impact of CytoSorb and CKRT on hemodynamics in pediatric patients with septic shock: the PedCyto study.Frontiers in pediatrics · 2023Article
- Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients.Critical care explorations · 2022Article
- Combined Extracorporeal Therapy with Pathogen Hemoadsorption and Cell-Directed Immunomodulation Strategies: A Two-Case Series.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCritically ill children with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT) are at increased risk of death. The selective cytopheretic device (SCD) promotes an immunomodulatory effect when circuit ionized calcium (iCa
methodsFour pediatric intensive care units (ICUs) enrolled children with AKI and multiorgan dysfunction receiving CKRT to receive the SCD integrated post-CKRT membrane. RCA was used to achieve a circuit iCa
resultsThe FDA target enrollment of 16 subjects completed the study from December 2016 to February 2020. Mean age was 12.3 ± 5.1 years, weight was 53.8 ± 28.9 kg, and median Pediatric Risk of Mortality II was 7 (range 2-19). Circuit iCa
conclusionOur data demonstrate that SCD therapy is feasible and safe in children who require CKRT. Although we cannot make efficacy claims, the 75% survival rate and 100% renal recovery rate observed suggest a possible favorable benefit-to-risk ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.